Bone Care International, Inc.

Lunar Corporation

Charles R Valliere

Charles W Bishop

Joyce C Knutson

Method of treating or preventing osteoporosis by administering orally a 1.alpha.-hydroxyprevitamin D. This previtamin D form increases vitamin D blood level without significant risk of hypercalcemia associated with other oral dosing of vitamin D forms. The 1.alpha.-hydroxyprevitamin is compounded into a pharmaceutical composition in combination with a pharmaceutically acceptable excipient.

Method and composition for treating or preventing osteoporosis

Method of treating psoriasis by administering orally a 1.alpha.-hydroxyprevitamin D. This previtamin D form treats psoriasis without significant risk of hypercalcemia associated with other oral dosing of vitamin D forms. The 1.alpha.-hydroxyprevitamin is compounded into a pharmaceutical composition in combination with a pharmaceutically acceptable excipient.

Oral 1.alpha.-hydroxyprevitamin D in composition and method for treating

Method of increasing activated vitamin D blood level by administering orally a 1.alpha.-hydroxyprevitamin D. This previtamin D form increases vitamin D blood level without significant risk of hypercalcemia associated with other oral dosing of vitamin D forms. The 1.alpha.-hydroxyprevitamin is compounded into a pharmaceutical composition in combination with a pharmaceutically acceptable excipient.

Oral 1.alpha.-hydroxyprevitamin D in methods for increasing blood level

Method of treating prostatic conditions such as prostate cancer and hyperplasia by administering 1.alpha.-hydroxyprevitamin D or activated vitamin D or a combination thereof in a sustained release form or a delayed and sustained release formulation. Both the sustained release form and the delayed, sustained release form deliver increased active vitamin D blood levels without significant risk of hypercalcemia associated with other oral dosing of vitamin D forms, to provide the beneficial effect to the diseased prostate tissue.

Method of treating prostatic diseases using delayed and/or sustained

Oral 1 .alpha.-hydroxyprevitamin D

Method of increasing activated vitamin D blood level by administering orally a 1.alpha.-hydroxyprevitamin D or a delayed and sustained release formulation of activated vitamin D or a combination thereof. Both the previtamin D form and the delayed and sustained release activated vitamin D formulation increase vitamin D blood level without significant risk of hypercalcemia associated with other oral dosing of vitamin D forms.

Oral 1.alpha.-hydroxyprevitamin D

This invention relates to delayed and sustained release oral medicaments and, more specifically, to delayed and sustained release activated vitamin D, oral medicament.

Growing community of inventors

Madison, WI, United States of America

Charles R Valliere